quizartinib + cytarabine + daunorubicin

Quizartinib + cytarabine + daunorubicin is a **three-drug combination regimen** used as an induction therapy for adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive. **Quizartinib** is a selective FLT3 inhibitor administered orally, which targets FLT3-ITD mutations that frequently occur in AML. **Cytarabine** is a nucleoside metabolic inhibitor (antimetabolite) used intravenously to inhibit DNA synthesis, and **daunorubicin** is an anthracycline antibiotic that intercalates DNA, inhibiting topoisomerase II and leading to cell death. This combination is administered as part of a "7+3" induction protocol (7 days cytarabine, 3 days daunorubicin, with quizartinib added from day 8) and was FDA-approved in 2023 for the FLT3-ITD+ AML population[4][2][1][7].